CCR4-targeted therapy in cutaneous T-cell lymphoma
Mené sur 372 patients atteints d'un lymphome cutané à cellules T, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du mogamulizumab, un anticorps monoclonal ciblant les récepteurs aux chimiokines CCR4, et du vorinostat, après l'échec d'au moins une ligne de thérapie systémique
Various neoplasms, including T-cell lymphomas and solid tumours, have high C-C chemokine receptor 4 (CCR4) expression. In physiological conditions, CCR4 plays a part in the homing of memory T cells to peripheral tissues, such as the skin. Importantly, cutaneous T-cell lymphomas, which arise from those skin resident memory lymphocytes, also express CCR4, opening avenues for therapeutic intervention
The Lancet Oncology , commentaire, 2017